Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SORD | Q00796 | 3/20 | 0.31 |
| ▸ | EGFR | P00533 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7715849 | 1.00 | SORD (0.31) | SORDEGFRHRH4TRPV3KDM4E | |
| SCHEMBL194327 | 0.88 | CCNA2 (0.33) | EGFRTRPV3KDM4EALDH1A1LMNA | |
| SCHEMBL7715595 | 0.88 | CCNA2 (0.33) | EGFRTRPV3KDM4EALDH1A1LMNA | |
| SCHEMBL194767 | 0.86 | CCNA2 (0.35) | TRPV3KDM4EALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL7719378 | 0.86 | CCNA2 (0.35) | TRPV3KDM4EALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL1186776 | 0.85 | TRPV3 (0.35) | TRPV3KDM4EALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL9270241 | 0.85 | TRPV3 (0.35) | TRPV3KDM4EALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL12872239 | 0.84 | TRPV3 (0.38) | TRPV3KDM4EALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL12872285 | 0.84 | HTR3A (0.34) | HRH4TRPV3KDM4EALDH1A1 | |
| SCHEMBL9275439 | 0.84 | HTR3A (0.34) | HRH4TRPV3KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2400961-B1 | MEDICINE COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS | BOEHRINGER INGELHEIM INT (DE) | 2017-11-22 | — | — | EP | claimed |
| US-8877758-B2 | Combinations of medicaments, containing PDE4-inhibitors and EP4-receptor-antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-04 | — | — | US | claimed |
| US-8759326-B2 | Drug combinations containing PDE4 inhibitors and NSAIDs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-06-24 | — | — | US | claimed |
| US-20140031343-A1 | DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-01-30 | — | — | US | claimed |
| US-8592400-B2 | Drug combinations containing PDE4 inhibitors and NSAIDs | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-11-26 | — | — | US | claimed |
| US-20130237527-A1 | COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4-INHIBITORS AND EP4-RECEPTOR-ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-09-12 | — | — | US | claimed |
| US-20120028932-A1 | DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-02 | — | — | US | claimed |
| EP-2400961-A1 | DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS | Boehringer Ingelheim International GmbH (DE) | 2012-01-04 | — | — | EP | claimed |
| WO-2010097332-A1 | DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | WO | claimed |
| EP-2400961-B1 | MEDICINE COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS | BOEHRINGER INGELHEIM INT (DE) | 2017-11-22 | — | — | EP | disclosed |
| EP-2205609-B1 | HETEROCYCLE SUBSTITUTED PIPERAZINO DIHYDROTHIENO PYRIMIDINES | BOEHRINGER INGELHEIM INT (DE) | 2017-03-29 | — | — | EP | disclosed |
| EP-2205609-B1 | HETEROCYCLE SUBSTITUTED PIPERAZINO DIHYDROTHIENO PYRIMIDINES | BOEHRINGER INGELHEIM INT (DE) | 2017-03-29 | — | — | EP | disclosed |
| US-9115142-B2 | Heterocycle-substituted piperazino-dihydrothienopyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-08-25 | — | — | US | disclosed |
| US-9115142-B2 | Heterocycle-substituted piperazino-dihydrothienopyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-08-25 | — | — | US | disclosed |
| US-20120028932-A1 | DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-02 | — | — | US | disclosed |
| EP-2400961-A1 | DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS | Boehringer Ingelheim International GmbH (DE) | 2012-01-04 | — | — | EP | disclosed |
| US-20100305102-A1 | HETEROCYCLE-SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-02 | — | — | US | disclosed |
| US-20100305102-A1 | HETEROCYCLE-SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-02 | — | — | US | disclosed |
| US-20100305102-A1 | HETEROCYCLE-SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-02 | — | — | US | disclosed |
| WO-2010097332-A1 | DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031343-A1 | DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS | PTGER4, PDE4A, PDE12 | SORD 1039/4885EGFR 4193/4885HRH4 67/4885 |
| US-20100305102-A1 | HETEROCYCLE-SUBSTITUTED PIPERAZINO-DIHYDROTHIENOPYRIMIDINES | SULT2A1, DPYD, HRH2 | SORD 1443/4885EGFR 480/4885HRH4 12/4885 |
| US-20130237527-A1 | COMBINATIONS OF MEDICAMENTS, CONTAINING PDE4-INHIBITORS AND EP4-RECEPTOR-ANTAGONISTS | PTGER4, PTGER1, PTGER3 | SORD 2937/4885EGFR 2119/4885HRH4 33/4885 |
| US-20120028932-A1 | DRUG COMBINATIONS CONTAINING PDE4 INHIBITORS AND NSAIDS | PTGER4, PDE4A, PDE3B | SORD 1484/4885EGFR 4135/4885HRH4 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.